Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, global sales and marketing, and product strategy. He most recently served as President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals, where he successfully guided the company’s operations and strategic direction from 2017 to 2021.

Prior to becoming CEO, Mr. Turgeon served as President & Chief Operating Officer (2014–2017) and as Senior Vice President & Chief Commercial Officer (2012–2014) at Spectrum Pharmaceuticals. During his tenure, he played a central role in building Spectrum’s commercial and development capabilities, positioning the company as a recognized leader in oncology innovation.

Before joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc., where he rose to the position of Vice President of Sales. At Amgen, he was instrumental in launching many of the company’s most successful drugs across oncology, inflammation and bone health, and was a key member of the original commercial team that helped establish Amgen as a global leader in biotechnology.

As Chief Operating Officer, Mr. Turgeon will oversee all operational aspects of Nouveau Biosciences, including clinical development execution, business operations, and commercial strategy, supporting the company’s mission to deliver next-generation cancer therapies to patients worldwide.